Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13742
Abstract: There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase… read more here.
Keywords: patients non; cell lung; osimertinib patients; non small ... See more keywords
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.2139/ssrn.4043414
Abstract: INTRODUCTION Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib… read more here.
Keywords: patients advanced; phase multicenter; osimertinib patients; dose osimertinib ... See more keywords